NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today. "With over twenty years of experience in the biopharmaceutical industry, Larry brings a proven track record of growing commercial businesses, successful mergers and acquisitions, and strong corporate governance, which are critical to driving SIGA's continued success and growth strategies forward," said Diem Nguyen, Chief Executive Officer.  "Larry will be instrumental in helping us expand our reach on a global scale and maximize the ben

NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company's Board of Directors. SIGA's current CEO, Dr. Phil Gomez, will retire from SIGA on January 26, 2024. "The appointment of Diem Nguyen as our new CEO marks a significant milestone for SIGA as we continue to expand our partnerships with governments across the world in global health security initiatives and medical countermeasure preparedness," said Josep

NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Phil Gomez, PhD, Chief Executive Officer of SIGA, has announced his intention to retire as CEO in 2023. SIGA's Board of Directors has initiated a search for a new CEO, and Dr. Gomez is expected to remain in position as CEO until his successor commences services as Chief Executive Officer of SIGA. "Serving as CEO of SIGA since 2016 has been a profoundly rewarding professional experience as we have taken a range of steps to strengthen and expand operations and worked diligently to respond to the global

10-Q - SIGA TECHNOLOGIES INC (0001010086) (Filer)

8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

10-Q - SIGA TECHNOLOGIES INC (0001010086) (Filer)

8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

Product Revenues for the Three and Nine months Ended September 30, 2024 were $9 million and $53 million, respectivelyReceived $122 Million of Procurement Orders from the U.S. Government in the Third QuarterCorporate Update Conference Call Today at 4:30 PM ET NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2024. "Building on strong momentum, SIGA received $122 million in orders during the third quarter, including a significant $112.5 million order for oral TPOXX under the 19C BARDA contract and a $9 million order for oral T

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into an agreement with Vanderbilt University to obtain a license to a portfolio of preclinical fully human monoclonal antibodies (mAbs) which could be used as potential treatments for a broad range of orthopoxviruses, including smallpox and mpox. Under the agreement, SIGA has exercised its option to license the exclusive rights to develop, manufacture, and commercialize these mAbs globally. "SIGA has cultivated deep expertise in orthopoxvirus, and we are thrilled to expand our pipeline with Va

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) --  SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into an agreement to supply TPOXX (tecovirimat) in Morocco. The contract was executed in response to a request from the Ministry of Health in Morocco to make the therapy available in the country and help prepare and protect its citizens against any potential mpox outbreak. Tecovirimat is approved in the U.S., Canada, and the EU, and while it has also been available in Africa through clinical trials and as part of the World Health Organization's emergency use access protocol, this agreement ma

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced a new contract with the U.S. Department of Defense (DOD) for the procurement of approximately $9 million of TPOXX® (Contract number: W911SR24C0030). This award is comprised primarily of oral TPOXX®, with a small amount of intravenous (IV) TPOXX®, and represents the third procurement contract award from the DOD over the past three years. SIGA has been collaborating with the DOD's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to develop the Post-exposure

Preliminary analysis shows the study did not reach statistical significance on its primary endpoint of tecovirimat being superior to placebo in lesion resolution for all patientsResults suggest tecovirimat provides clinical benefit vs. placebo in two important patient populations: those treated early and those with severe diseaseResults affirm tecovirimat's strong safety profileMultiple additional clinical trials evaluating tecovirimat for mpox continue NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced topline results from a preliminary analysis of the PALM 007 (Tecovirimat fo

Generated Product Sales of $21 Million in the Second Quarter, and $45 Million in the Six Months Ended June 30, 2024Received $113 Million Procurement Order from U.S. Government for Oral TPOXX in JulyCorporate Update Conference Call Today at 4:30 PM ET NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2024. "SIGA continued to perform well again this quarter, generating $21 million of revenues, including $18 million of IV TPOXX sales to the U.S. Government," said Diem Nguyen, Chief Executive Officer. "For the first six months of the

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 1, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-17

NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that the U.S. Department of Health and Human Services exercised a procurement option for the delivery of approximately $113 million of oral TPOXX® treatment courses. "Building on the orders received in 2023 from the U.S. government and 15 international customers, this $113 million order from the U.S. government will enhance orthopoxvirus preparedness and support sizable and consistent action when needed to help ensure public health from natural, accidental, or intentional threats," said Diem Nguyen, Chief Executive Officer. "We are

NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on global health and infectious diseases, announced today an agreement to expand access to TPOXX (tecovirimat) to the member states in the Association of Southeast Asian Nations (ASEAN), a political and economic union in the region. This agreement, which was signed by the Ministry of Health of the Government of Brunei Darussalam on behalf of ASEAN Health Sector, is significant as it reflects the use of ASEAN funds to support preparedness activities for potential public health events. The contract was coordinated by SIGA and its international promotion partner, Meridian Med

Product Revenues for the Three and Nine months Ended September 30, 2024 were $9 million and $53 million, respectivelyReceived $122 Million of Procurement Orders from the U.S. Government in the Third QuarterCorporate Update Conference Call Today at 4:30 PM ET NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2024. "Building on strong momentum, SIGA received $122 million in orders during the third quarter, including a significant $112.5 million order for oral TPOXX under the 19C BARDA contract and a $9 million order for oral T

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-

Generated Product Sales of $21 Million in the Second Quarter, and $45 Million in the Six Months Ended June 30, 2024Received $113 Million Procurement Order from U.S. Government for Oral TPOXX in JulyCorporate Update Conference Call Today at 4:30 PM ET NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2024. "SIGA continued to perform well again this quarter, generating $21 million of revenues, including $18 million of IV TPOXX sales to the U.S. Government," said Diem Nguyen, Chief Executive Officer. "For the first six months of the

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 1, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-17

Generated Product Sales of $24 Million and Pre-tax Operating Income of $11 MillionCorporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2024. "SIGA delivered strong results in the first quarter, with product revenues of $24 million and pre-tax operating income of $11 million, both up over the comparable quarter in 2023," said Diem Nguyen, Chief Executive Officer. "First quarter financial performance is a testament to our focus on financial and operational excellence, the value of our TPOXX®

NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, May 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at www.siga.com under the 'Events & Presentations' tab in the Investor Relations section, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by diali

• Increased Product Sales to $131 Million in 2023 • Grew Pre-tax Operating Income to $84 Million in 2023 • Declared Today a Special Cash Dividend of $0.60 per Share • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2023. "In 2023, SIGA had approximately $131 million in product revenues and approximately $84 million of pre-tax operating income," stated Diem Nguyen, Chief Executive Officer. "These financial results represent a significant increase over the 2022 financ

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company's common stock. This represents an increase of $0.15 per share, or 33%, over the cash dividend paid in June 2023. The dividend is payable on April 11, 2024, to shareholders of record at the close of business on March 26, 2024. "Our operating performance, strong cash resources, and continued confidence in SIGA's business position us to declare a special cash dividend for our shareholders," said Diem Nguyen, Chief Executive Officer. "The significant

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 12th, 2024. Participating in the call will be Dr. Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at www.siga.com under the 'Events & Presentations' tab in the Investor Relations section, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the ca

- In Third Quarter, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® - - In October, Joint Procurement Framework Contract was signed by European Commission with Anticipated Initial Orders by Participating Countries of Approximately $18 Million for Oral TPOXX® (Tecovirimat) - - Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2023. "SIGA's third quarter and year-to-date financial results reflect a relativ

SC 13G - SIGA TECHNOLOGIES INC (0001010086) (Subject)

SC 13G/A - SIGA TECHNOLOGIES INC (0001010086) (Subject)

SC 13G - SIGA TECHNOLOGIES INC (0001010086) (Subject)

SC 13D/A - SIGA TECHNOLOGIES INC (0001010086) (Subject)

SC 13D/A - SIGA TECHNOLOGIES INC (0001010086) (Subject)

SC 13D/A - SIGA TECHNOLOGIES INC (0001010086) (Subject)

SC 13D - SIGA TECHNOLOGIES INC (0001010086) (Subject)

With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Patterson Companies, Inc. (NASDAQ:PDCO) to report quarterly earnings at $0.83 per share on revenue of $1.71 billion before the opening bell, according to data from Benzinga Pro. Patterson shares gained 3.9% to $23.75 in after-hours trading. JELD-WEN Holding, Inc. (NYSE:JELD) named Samantha L. Stoddard as its Chief Financial Officer, succeeding Julie C. Albrecht as EVP, CFO effective July 1. JELD-WEN shares fell 4.5% to $3.15 in the after-hours trading session. Analysts are expecting KB Home (NYSE:KBH) to post quarterly earnings at

Calidi Biotherapeutics, Inc. (NYSE:CLDI) stock is trading higher after the company announced Monday its collaborating with SIGA Technologies (NASDAQ:SIGA). The Details: Calidi and SIGA are partnering in order to advance Calidi’s RTNova virotherapy for lung cancer and metastatic solid tumors. Calidi will focus on the development of RTNova, an enveloped vaccinia virus, that is designed to move through the bloodstream, target multiple tumor sites and kill tumor cells. SIGA will provide TPOXX, an antiviral agent effective against vaccinia virus. The companies will work to test TPOXX’s capabilities as a way to manage RTNova’s spread. This therapeutic approach will simplify treatment admi

Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that it entered into a collaboration agreement with SIGA Technologies (NASDAQ:SIGA) in the first quarter of 2024, to support the development of Calidi's systemic and targeted RTNova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types. Calidi will initially focus on developing the RTNova platform for lung cancer and metastatic (or advanced stage) solid tumors which account for the majority of cancer deaths. The long-term collaboration between Calidi and SIGA aims to harness th

Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial results and issued second-quarter revenue guidance below estimates. Upstart reported first-quarter revenue of $128 million, which beat the consensus estimate of $124.867 million, according to Benzinga Pro. Upstart expects second-quarter revenue of approximately $125 million versus estimates of $140.83 million. The company anticipates a second-quarter adjusted EBITDA loss of approximately $25 million. Upstart shares dipped 10.3% to $21.96 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Reborn Coffee, In

Gainers MaxCyte (NASDAQ:MXCT) shares rose 26.5% to $4.97 during Wednesday's regular session. The company's market cap stands at $519.4 million. The company's, Q1 earnings came out yesterday. Elanco Animal Health (NYSE:ELAN) stock moved upwards by 25.25% to $16.93. The market value of their outstanding shares is at $8.3 billion. The company's, Q1 earnings came out today. Globus Medical (NYSE:GMED) shares rose 22.17% to $62.75. The company's market cap stands at $8.4 billion. The company's, Q1 earnings came out yesterday. Clover Health Investments (NASDAQ:CLOV) stock moved upwards by 20.63% to $0.89. The company's market cap stands at $442.6 million. As per the press release, Q1 earnings c